Two large phase 3 trials found that oral semaglutide 14 mg did not slow cognitive or functional decline over 104 weeks in ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 23, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ('HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has initiated a ...

One of these assets is catalyst-driven; the other isn't.

Oral semaglutide (a GLP-1 pill) is not effective at slowing progression in patients with mild Alzheimer's disease, finds the ...

Kymera Therapeutics Inc. (NASDAQ:KYMR) is one of the most promising stocks under $100 to buy. On March 10, Kymera ...

Greenwich LifeSciences has added City of Hope to its Phase III FLAMINGO-01 clinical trial, which is investigating the GLSI-100 immunotherapy for preventing breast cancer recurrenc ...

Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Interim systemic lung cancer data with Olvi-Vec demonstrated partial responses in ...

Verastem (VSTM) stock receives a "Buy" rating, driven by progress in KRAS G12D-targeted therapies and multiple 2026 catalysts. Read the full analysis here.

Company Served as Sponsor and Provided Operational Leadership for Study Conducted in Partnership with TGen and Virta ...

TenoMiR to Progress to Phase 3 Study for Lateral Epicondylitis, Making it One of the Most Advanced microRNA Clinical Programs GLASGOW, Scotland, March 19, 2026 (GLOBE NEWSWIRE) -- Causeway ...

AtaiBeckley is a clinical-stage psychedelic biotech targeting TRD and SAD, with BPL-003 as its lead value driver. Learn more about ATAI stock here.

BACKGROUND: Premature atrial contractions (PACs) are independently associated with atrial fibrillation, stroke, and heart failure, yet no pharmacological therapy is approved for PAC suppression.